FY2028 EPS Estimates for Genmab A/S Raised by William Blair

Genmab A/S (NASDAQ:GMAB) – Investment analysts at William Blair raised their FY2028 earnings per share (EPS) estimates for shares of Genmab A/S in a research note issued to investors on Monday, March 10th. William Blair analyst M. Phipps now expects that the company will post earnings per share of $4.06 for the year, up from their prior estimate of $4.02. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Genmab A/S’s current full-year earnings is $1.45 per share.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share for the quarter, beating analysts’ consensus estimates of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%.

Other equities research analysts also recently issued research reports about the company. Sanford C. Bernstein upgraded Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Friday, December 20th. HC Wainwright reiterated a “buy” rating and set a $50.00 price target on shares of Genmab A/S in a research note on Thursday, January 23rd. Leerink Partners raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price objective for the company in a research note on Thursday, February 13th. Leerink Partnrs raised shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a research note on Thursday, February 13th. Finally, Truist Financial decreased their price target on shares of Genmab A/S from $50.00 to $45.00 and set a “buy” rating for the company in a research report on Tuesday. Four investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $41.33.

Genmab A/S Stock Down 0.2 %

Shares of NASDAQ GMAB opened at $20.21 on Wednesday. The business’s 50 day moving average is $21.28 and its two-hundred day moving average is $22.52. Genmab A/S has a 52-week low of $18.64 and a 52-week high of $31.88. The firm has a market cap of $13.37 billion, a price-to-earnings ratio of 11.61, a PEG ratio of 2.65 and a beta of 0.98.

Institutional Investors Weigh In On Genmab A/S

Several institutional investors have recently modified their holdings of GMAB. Charles Schwab Investment Management Inc. raised its stake in Genmab A/S by 94.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 26,104 shares of the company’s stock valued at $636,000 after buying an additional 12,654 shares in the last quarter. AIMZ Investment Advisors LLC purchased a new stake in Genmab A/S during the fourth quarter worth approximately $3,525,000. HighTower Advisors LLC acquired a new position in Genmab A/S in the third quarter valued at approximately $273,000. Verition Fund Management LLC purchased a new position in Genmab A/S in the third quarter valued at approximately $709,000. Finally, FMR LLC raised its holdings in Genmab A/S by 13.5% during the third quarter. FMR LLC now owns 278,194 shares of the company’s stock worth $6,782,000 after purchasing an additional 33,076 shares in the last quarter. 7.07% of the stock is owned by hedge funds and other institutional investors.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.